Market news

SAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / , Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced that Richard Langford, Chief Medical Officer of Cy Biopharma, has been selected to present in person at the U.

SAN DIEGO, CA / ACCESS Newswire / September 2, 2026 / , Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced its participation in the following upcoming investors conferences and industry events.

Detailed price information for Ensysce Biosciences Inc (ENSC-Q) from The Globe and Mail including charting and trades.

By Brad Sorensen, CFA NASDAQ: ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ: ENSC) is entering what may be the most consequential period in its history. The clinical-stage biotechnology company has spent years developing technologies intended to make powerful pain medications safer, but the recently completed acquisition of Cy Biopharma materially changes the investment

Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain SyndromeUp to $77 million in new funding with the acquisition of Cy BiopharmaCompany to host a Corporate Update Call on Tuesday, August 18, 2026, at 11:00 a.m. ET SAN DIEGO, ...

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC) shares

By Brad Sorensen, CFA NASDAQ: ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ: ENSC) has focused on developing innovative pharmaceutical technologies designed to make prescription opioids significantly safer. Through its proprietary Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms, the company is developing next-generation pain

Investor interest in low-priced growth stocks continues to build as companies across defense technology, artificial intelligence, biotechnology, digital media, and cross-border logistics announce significant business developments. Several stocks tr...

Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings (NASDAQ:ADGM) stock

Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million. TransCode Therapeutics (NASDAQ:RNAZ)

Ensysce Biosciences (NASDAQ:ENSC) has received a $5. 3 million award from the National Institute on Drug Abuse (NIDA), completing a multi-year federal grant totaling $15.

Funds Advance FDA-Designated Breakthrough Therapy First-in-Class Opioid with Oral Overdose-Protection SAN DIEGO, CA / ACCESS Newswire / July 14, 2026 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical ...